East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Adalimumab
Adalimumab
Routinely available
NICE (TA383 (SMC 858/13))
04/12/2024

Indication

For the treatment of adults with severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis (nr-axSpA) but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have had an inadequate response to, or are int...

For the treatment of adults with severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis (nr-axSpA) but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).

Therapeutic Area

Musculoskeletal and joint diseases

Status Description

Routinely available in line with national guidance

Formulation

-

Comments

Refer to pathway or local board guidelines for preferred formulation

Link to Advice

TA383 (SMC 858/13)

Advice Published

01/02/2016